Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases

2022/06/15 by Kevin M. Sullivan, Kevin M Sullivan, Xiuyun Jiang +33 · 26 citations
Medicine · #CAR-T cell therapy research #Cancer Immunotherapy and Biomarkers #Cancer Cells and Metastasis

paper · pdf · doi:10.1136/gutjnl-2021-325808

Abstract

OBJECTIVE: Programmed cell death protein 1 (PD-1) checkpoint inhibition and adoptive cellular therapy have had limited success in patients with microsatellite stable colorectal cancer liver metastases (CRLM). We sought to evaluate the effect of interleukin 10 (IL-10) blockade on endogenous T cell and chimeric antigen receptor T (CAR-T) cell antitumour function in CRLM slice cultures. DESIGN: We created organotypic slice cultures from human CRLM (n=38 patients' tumours) and tested the antitumour effects of a neutralising antibody against IL-10 (αIL-10) both alone as treatment and in combination with exogenously administered carcinoembryonic antigen (CEA)-specific CAR-T cells. We evaluated slice cultures with single and multiplex immunohistochemistry, in situ hybridisation, single-cell RNA sequencing, reverse-phase protein arrays and time-lapse fluorescent microscopy. RESULTS: T cells without exhaustion transcription changes, and increased human leukocyte antigen - DR isotype (HLA-DR) expression of macrophages. The antitumour effects of αIL-10 were reversed by major histocompatibility complex class I or II (MHC-I or MHC-II) blockade, confirming the essential role of antigen presenting cells. Interrupting IL-10 signalling also rescued murine CAR-T cell proliferation and cytotoxicity from myeloid cell-mediated immunosuppression. In human CRLM slices, αIL-10 increased CEA-specific CAR-T cell activation and CAR-T cell-mediated cytotoxicity, with nearly 70% carcinoma cell apoptosis across multiple human tumours. Pretreatment with an IL-10 receptor blocking antibody also potentiated CAR-T function. CONCLUSION: Neutralising the effects of IL-10 in human CRLM has therapeutic potential as a stand-alone treatment and to augment the function of adoptively transferred CAR-T cells.

Cited by

• Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence
• Recent advances in CAR-T cells therapy for colorectal cancer. [europepmc]
• Immunotherapies catering to the unmet medical need of cold colorectal cancer. [europepmc]
• Efferocytosis drives myeloid NLRP3 dependent inflammasome signaling secretion of IL-1β to promote tumor growth. [europepmc]
• Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. [europepmc]
• Relationship between Epithelial-to-Mesenchymal Transition and Tumor-Associated Macrophages in Colorectal Liver Metastases. [europepmc]
• Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. [europepmc]
• The role of myeloid-derived suppressor cells in liver cancer. [europepmc]
• Culture of vibrating microtome tissue slices as a 3D model in biomedical research. [europepmc]
• Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. [europepmc]
• Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor. [europepmc]
• C1q + tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. [europepmc]
• Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. [europepmc]
• GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers. [europepmc]
• Immunotherapy for colorectal cancer: insight from inherited genetics. [europepmc]
• Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. [europepmc]
• B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors. [europepmc]
• Signaling pathways in colorectal cancer implications for the target therapies. [europepmc]
• Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. [europepmc]
• Advancements in 3D In Vitro Models for Colorectal Cancer. [europepmc]
• Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy. [europepmc]
• Advances in targeting tumor microenvironment for immunotherapy. [europepmc]
• Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies. [europepmc]
• Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. [europepmc]
• New insights on anti-tumor immunity of CD8 + T cells: cancer stem cells, tumor immune microenvironment and immunotherapy. [europepmc]
• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. [europepmc]

Related

• Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
• Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
• Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
• Single‐Cell Profiling Reveals Distinct Immune Hallmarks in Untreated Primary Colorectal and Liver Metastasis Cancers
• IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression